Treatment results of high-risk defined by NCI criteria childhood acute lymphoblastic leukemia in AIEOP-ALL studies over two decades.

被引：0
|
作者：
Aricò, M
Conter, V
Valsecchi, MG
Rizzari, C
Barisone, E
Messina, C
Lo Nigro, L
Pinta, MF
De Rossi, G
Pession, A
Testi, AM
Santoro, N
Di Tullio, MT
Micalizzi, C
Favre, C
Lippi, A
Rondelli, R
Silvestri, D
Biondi, A
Basso, G
Masera, G
机构：
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2001
引用
收藏
页码：464A / 465A
页数：2
相关论文
共 50 条
  • [21] Early Diagnosis and Targeted Treatment of Very High-Risk Childhood Acute Lymphoblastic Leukemia - The I-BFM Approach
    Stanulla, M.
    Cario, G.
    Meissner, B.
    Breithaupt, P.
    Schrauder, A.
    Moericke, A.
    Bourquin, J. P.
    Schrappe, M.
    KLINISCHE PADIATRIE, 2011, 223 (01): : 51 - 51
  • [22] Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial
    Andishe Attarbaschi
    Georg Mann
    Martin Zimmermann
    Peter Bader
    Elena Barisone
    Giuseppe Basso
    Andrea Biondi
    Gunnar Cario
    Gianni Cazzaniga
    Antonella Colombini
    Christian Flotho
    Michaela Kuhlen
    Peter Lang
    Melchior Lauten
    Christin Linderkamp
    Franco Locatelli
    Luca Lo Nigro
    Anja Möricke
    Felix Niggli
    Renate Panzer-Grümayer
    Rosanna Parasole
    Christina Peters
    Maria Caterina Putti
    Carmelo Rizzari
    Meinolf Suttorp
    Maria Grazia Valsecchi
    Valentino Conter
    Martin Schrappe
    Leukemia, 2020, 34 : 1694 - 1700
  • [23] High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia: Results of protocol ALL VI from the Dutch childhood leukemia study group
    Veerman, AJP
    Hahlen, K
    Kamps, WA
    VanLeeuwen, EF
    DeVaan, GAM
    Solbu, G
    Suciu, S
    VanWering, ER
    VanderDoesVandenBerg, A
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) : 911 - 918
  • [24] Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial
    Attarbaschi, Andishe
    Mann, Georg
    Zimmermann, Martin
    Bader, Peter
    Barisone, Elena
    Basso, Giuseppe
    Biondi, Andrea
    Cario, Gunnar
    Cazzaniga, Gianni
    Colombini, Antonella
    Flotho, Christian
    Kuhlen, Michaela
    Lang, Peter
    Lauten, Melchior
    Linderkamp, Christin
    Locatelli, Franco
    Lo Nigro, Luca
    Moericke, Anja
    Niggli, Felix
    Panzer-Gruemayer, Renate
    Parasole, Rosanna
    Peters, Christina
    Putti, Maria Caterina
    Rizzari, Carmelo
    Suttorp, Meinolf
    Valsecchi, Maria Grazia
    Conter, Valentino
    Schrappe, Martin
    LEUKEMIA, 2020, 34 (06) : 1694 - 1700
  • [25] Impact of Additional Intensive L-Asparaginase Therapy during Consolidation Phase for High-Risk Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial in the AIEOP-BFM ALL 2009 Protocol
    Conter, Valentino
    Valsecchi, Maria Grazia
    Cario, Gunnar
    Zimmermann, Martin
    Attarbaschi, Andishe
    Stary, Jan
    Niggli, Felix
    Dalla Pozza, Luciano
    Elitzur, Sarah
    Silvestri, Daniela
    Locatelli, Franco
    Moericke, Anja
    Engstler, Gernot
    Smisek, Petr
    Bodmer, Nicole
    Barbaric, Draga
    Izraeli, Shai
    Rizzari, Carmelo
    Boos, Joachim
    Buldini, Barbara
    Lanvers-Kaminsky, Claudia
    Cazzaniga, Giovanni
    Gruhn, Bernd
    Biondi, Andrea
    Schrappe, Martin
    BLOOD, 2022, 140
  • [26] Reduced Intensity Delayed Intensification in Standard-Risk Patients Defined By Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: Results of an International Randomized Trial in 1164 Patients (Trial AIEOP-BFM ALL 2000)
    Schrappe, Martin
    Zimmermann, Martin
    Moricke, Anja
    Mann, Georg
    Valsecchi, Maria Grazia
    Bartram, Claus R.
    Biondi, Andrea
    Panzer-Grumayer, Renate
    Beier, Rita
    Cario, Gunnar
    Locatelli, Franco
    Basso, Giuseppe
    Niggli, Felix
    Arico, Maurizio
    Conter, Valentino
    BLOOD, 2016, 128 (22)
  • [27] A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood 'high-risk' acute lymphoblastic leukaemia:: a study of the AIEOP group
    Testi, AM
    Del Giudice, I
    Arcese, W
    Moleti, ML
    Giona, F
    Basso, G
    Biondi, A
    Conter, V
    Messina, C
    Rondelli, R
    Micozzi, A
    Micalizzi, C
    Barisone, E
    Locatelli, F
    Dini, G
    Aricò, M
    Casale, F
    Comis, M
    Ladogana, S
    Lippi, A
    Mura, R
    Pinta, MF
    Santoro, N
    Valsecchi, MG
    Masera, G
    Mandelli, F
    BRITISH JOURNAL OF HAEMATOLOGY, 2002, 118 (03) : 741 - 747
  • [28] Prospective evaluation of minimal residual disease (MRD) in high-risk childhood acute lymphoblastic leukemia in the ongoing trial ALL-BFM 2000
    Schrauder, A
    Flohr, T
    Zimmermann, M
    Koch, D
    Stanulla, M
    Lauten, M
    Welte, K
    Bartram, C
    Schrappe, M
    BONE MARROW TRANSPLANTATION, 2002, 30 : S60 - S60
  • [29] The Outcome of Childhood High-Risk Acute Lymphoblastic Leukemia: 10 Years of Experience with the ALL-BFM 95 Protocol in Chinese Single Centre
    Ruan, Yongsheng
    Wu, Xuedong
    Li, Chunfu
    Feng, Xiaoqin
    BLOOD, 2014, 124 (21)
  • [30] Outcome of allogeneic BMT in high-risk childhood T-Cell acute lymphoblastic leukemia (HR-T-ALL) compared to treatment with chemotherapy alone: results from trials ALL-BFM 90 and ALL-BFM 95
    Schrauder, A
    Reiter, A
    Zimmermann, M
    Klingebiel, T
    Mann, G
    Welte, K
    Schrappe, M
    BONE MARROW TRANSPLANTATION, 2002, 29 : S7 - S8
12345